<article id="world_page" class="slide" data-ag-slide-name="World Page">
    <div class="basic">
      <h1 id="wealth_of_evidence_pre_header" data-ag-editable="World Page Pre Main Title">Strong body of evidence</h1>
      <h1 id="wealth_of_evidence_post_header" class="wealth_of_evidence_hidden_content" data-ag-editable="World Page Post Main Title">Study sites for published lipegfilgrastim trials to date</h1>
      <div id="wealth_of_evidence_pre_top_copy" class="body_of_evidence_top_copy" data-ag-editable="World Page Pre Top Copy"><strong>More than 9 tumour types</strong> and <strong>several chemotherapy regimens</strong> investigated in <strong>more than 30 clinical trials</strong> with Neulasta<sup>®</sup> worldwide<sup>1–3</sup></div>
      <div id="wealth_of_evidence_post_top_copy" class="body_of_evidence_top_copy wealth_of_evidence_hidden_content" data-ag-editable="World Page Post Top Copy"><strong>No phase III/IV study sites and clinical research experience</strong> in US/Western Europe publicly available for lipegfilgrastim to date<sup>1,2</sup></div>
      <div id="world_page_map_holder">
         <div id="world_page_map_blue_overlay"></div>
         <div id="world_page_map_grey_overlay"></div>
      </div>
    </div>
    
    <!-- Reference Information Strong Starts -->
    <div class="lightbox_data" id="world_page_refs_strong">
       <div class="main_content_style">
          <p><strong data-ag-editable="World Page References Strong Title">References:</strong></p>
          <div data-ag-editable="World Page References Strong List">
             <ol>
                <li>Gregory SA <em>et al</em>. Evaluation of reported bone pain in cancer patients receiving chemotherapy in pegfilgrastim clinical trials: a retrospective analysis. Community Oncology 2010; 7(7):297-308</li>
                <li>Knop S <em>et al</em>. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood. 2009; 113(18):4137-4143</li>
                <li>Neulasta<sup>®</sup>, Summary of Product Characteristics, July 2013, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000420/WC500025945.pdf</li>
             </ol>
          </div>
       </div>
    </div>
    <!-- Reference Information Strong Ends -->
    <!-- Reference Information Weak Starts -->
    <div class="lightbox_data" id="world_page_refs_weak">
       <div class="main_content_style">
          <p><strong data-ag-editable="World Page References Weak Title">References:</strong></p>
          <div data-ag-editable="World Page References Weak List">
             <ol>
                <li>http://www.controlled-trials.com/ISRCTN55761467/, accessed September 2013</li>
                <li>http://www.controlled-trials.com/ISRCTN18217390/, accessed September 2013</li>
             </ol>
          </div>
       </div>
    </div>
    <!-- Reference Information Weak Ends -->
</article>